Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group; Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR. Kulbe H, et al. Among authors: charles ka. Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7. Cancer Res. 2012. PMID: 22065722 Free PMC article.
Tumour necrosis factor-alpha as a tumour promoter.
Szlosarek P, Charles KA, Balkwill FR. Szlosarek P, et al. Among authors: charles ka. Eur J Cancer. 2006 Apr;42(6):745-50. doi: 10.1016/j.ejca.2006.01.012. Epub 2006 Mar 6. Eur J Cancer. 2006. PMID: 16517151 Review.
"Re-educating" tumor-associated macrophages by targeting NF-kappaB.
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. Hagemann T, et al. Among authors: charles ka. J Exp Med. 2008 Jun 9;205(6):1261-8. doi: 10.1084/jem.20080108. Epub 2008 May 19. J Exp Med. 2008. PMID: 18490490 Free PMC article.
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF. Brown ER, et al. Among authors: charles ka. Ann Oncol. 2008 Jul;19(7):1340-1346. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5. Ann Oncol. 2008. PMID: 18325912 Free article. Clinical Trial.
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Harrison ML, et al. J Clin Oncol. 2007 Oct 10;25(29):4542-9. doi: 10.1200/JCO.2007.11.2136. J Clin Oncol. 2007. PMID: 17925549 Clinical Trial.
41 results